Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TAAR1 | Q96RJ0 | 4/20 | 0.60 |
| ▸ | HTR3E | A5X5Y0 | 1/20 | 0.53 |
| ▸ | HTR3B | O95264 | 1/20 | 0.53 |
| ▸ | HTR3A | P46098 | 1/20 | 0.53 |
| ▸ | HTR3D | Q70Z44 | 1/20 | 0.53 |
| ▸ | HTR3C | Q8WXA8 | 1/20 | 0.53 |
| ▸ | IDO1 | P14902 | 4/20 | 0.52 |
| ▸ | PNMT | P11086 | 1/20 | 0.52 |
| ▸ | SLC6A2 | P23975 | 1/20 | 0.50 |
| ▸ | SLC6A4 | P31645 | 1/20 | 0.50 |
| ▸ | SLC6A3 | Q01959 | 1/20 | 0.50 |
| ▸ | AOC3 | Q16853 | 1/20 | 0.50 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.50 |
| ▸ | PKM | P14618 | 1/20 | 0.48 |
| ▸ | NPC1 | O15118 | 1/20 | 0.47 |
| ▸ | RAB9A | P51151 | 1/20 | 0.47 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.44 |
| ▸ | LMNA | P02545 | 2/20 | 0.44 |
| ▸ | HTT | P42858 | 1/20 | 0.44 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29538519 | 1.00 | TAAR1 (0.60) | TAAR1HTR3EHTR3BHTR3AHTR3D | |
| SCHEMBL5584302 | 0.86 | TAAR1 (0.52) | TAAR1HTR3EHTR3BHTR3AHTR3D | |
| SCHEMBL1044928 | 0.86 | TAAR1 (0.56) | TAAR1HTR3EHTR3BHTR3AHTR3D | |
| SCHEMBL1804680 | 0.84 | TAAR1 (0.54) | TAAR1HTR3EHTR3BHTR3AHTR3D | |
| SCHEMBL6740216 | 0.84 | TAAR1 (0.71) | TAAR1HTR3EHTR3BHTR3AHTR3D | |
| SCHEMBL6062588 | 0.82 | TAAR1 (0.52) | TAAR1HTR3EHTR3BHTR3AHTR3D | |
| SCHEMBL7037675 | 0.82 | TAAR1 (0.52) | TAAR1HTR3EHTR3BHTR3AHTR3D | |
| SCHEMBL2963562 | 0.81 | TAAR1 (0.63) | TAAR1IDO1PNMTTDP1SMN1; SMN2 | |
| SCHEMBL29924786 | 0.81 | TAAR1 (0.63) | TAAR1IDO1PNMTTDP1SMN1; SMN2 | |
| SCHEMBL31203 | 0.81 | TDP1 (0.55) | TAAR1TDP1HTTHIF1ATSHR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 440 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-119491240-A | Method for preparing benzyl carboxylic acid compound by taking carbon dioxide as raw material | 哈尔滨工业大学（深圳） | 2025-02-21 | — | — | CN | claimed |
| CN-117821525-A | Enzymatic synthesis method of halohydrin medicine chiral building block | 宁波酶赛生物工程有限公司 | 2024-04-05 | — | — | CN | claimed |
| CN-113846082-B | Halohydrin dehalogenase mutant, encoding gene, recombinant vector, recombinant genetic engineering bacteria and application thereof | 华东理工大学 | 2023-06-23 | — | — | CN | claimed |
| CN-113333018-A | Preparation method and application of supported catalyst for preparing halogenated styrene | 中触媒新材料股份有限公司 | 2021-09-03 | — | — | CN | claimed |
| CN-110669743-A | P450 monooxygenase mutant from deinococcus radiodurans and application thereof | 遵义医科大学 | 2020-01-10 | — | — | CN | claimed |
| CN-103420747-A | Synthetic method for olefin compounds | SUZHOU OST ADVANCED MATERIALS CO LTD | 2013-12-04 | — | — | CN | claimed |
| US-6989052-B1 | Phase change ink printing process | XEROX CORPORATION (US) | 2006-01-24 | — | — | US | claimed |
| US-20060004123-A1 | PHASE CHANGE INK PRINTING PROCESS | XEROX CORPORATION | 2006-01-05 | — | — | US | claimed |
| EP-0446301-B1 | PREPARATION OF BIARYL COMPOUNDS | EASTMAN CHEM CO (US) | 1994-11-23 | — | — | EP | claimed |
| US-4820672-A | REACTING MAGNESIUM OR ORGANOMAGNESIUM COMPOUNDS, HYDROGEN CHLORIDE, CHLOROALCOHOL, BETA-ALKYL SUBSTITUTED ALCOHOLS; POLY CAT OR SUPPORTS | LITHIUM CORPORATION OF AMERICA (US) | 1989-04-11 | — | — | US | claimed |
| US-20260035381-A1 | COMPOUNDS AND COMPOSITIONS AND USES THEREOF | SUMITOMO PHARMA AMERICA, INC. (US) | 2026-02-05 | — | — | US | disclosed |
| EP-4680612-A1 | CHEMICAL COMPOUNDS | AN2 Therapeutics, Inc. (US) | 2026-01-21 | — | — | EP | disclosed |
| CN-116514880-B | Novel PNNO and PNNN chiral tetradentate ligand and application thereof in asymmetric hydrogenation | 凯特立斯（深圳）科技有限公司 | 2025-06-10 | — | — | CN | disclosed |
| EP-4490150-A1 | AMIDO CYCLOPROPYL DERIVATIVES AS LPA RECEPTOR INHIBITORS | Chiesi Farmaceutici S.p.A. (IT) | 2025-01-15 | — | — | EP | disclosed |
| WO-2025007074-A1 | CHEMICAL COMPOUNDS | REACTIVE BIOSCIENCES, INC. (US) | 2025-01-02 | — | — | WO | disclosed |
| EP-0222414-A2 | Novel organic selenium compounds | NIPPON KAYAKU KABUSHIKI KAISHA (JP) | 1987-05-20 | — | — | EP | disclosed |
| US-4629781-A | STRONG ACIDOLYSIS CONTROLLED BY THE USE OF SOLVENT, ACID, CONCENTRATION AND HEATING | GRUPPO LEPETIT S.P.A. (IT) | 1986-12-16 | — | — | US | disclosed |
| EP-0198440-A2 | Process for preparing optically active 2-halo-1-phenyl ethanol | KANEGAFUCHI KAGAKU KOGYO KABUSHIKI KAISHA (JP) | 1986-10-22 | — | — | EP | disclosed |
| EP-0146053-A2 | Chemical process for preparing antibiotic L 17392 (Deglucoteicoplanin) and its salts | GRUPPO LEPETIT S.p.A. (IT) | 1985-06-26 | — | — | EP | disclosed |
| EP-0082006-A2 | Method for producing vicinal dihalogenated products and uses thereof, and process for preparing epoxides using the same | CETUS CORPORATION (US) | 1983-06-22 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20260035381-A1 | COMPOUNDS AND COMPOSITIONS AND USES THEREOF | ADH1C, HTR6, CNR1 | TAAR1 97/4885HTR3E 211/4885HTR3B 88/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.